420 - Ketamine treatment in geriatric depression

Treatment resistant depression can be very disabling and has a significant negative impact on patient, their family or caregivers, the society. There is growing evidence efficacy safety of ketamine for treatment depression. Ketamine racemate consisting esketamine arketamine, an N-methyl D-aspartate receptor antagonist comes in different formulations fact intranasal FDA-approved US. Despite existing FDA approval depression, data older individuals remains limited. Late life especially those that are disabling, with functional cognitive impairments, increased morbidity mortality, psychosocial burdens. This presentation describes outcomes 2 cases who were treated ketamine. One improved, one did not. The scarce available literature use geriatric population shows well tolerated effective. Remission rates 3 separate show remission 46.5%, 57% 69.5% respectively. discussion will include review mechanism action as novel antidepressant, mixed its role late practical operational aspects relevant to running clinic.